JP2018121657A5 - - Google Patents

Download PDF

Info

Publication number
JP2018121657A5
JP2018121657A5 JP2018085040A JP2018085040A JP2018121657A5 JP 2018121657 A5 JP2018121657 A5 JP 2018121657A5 JP 2018085040 A JP2018085040 A JP 2018085040A JP 2018085040 A JP2018085040 A JP 2018085040A JP 2018121657 A5 JP2018121657 A5 JP 2018121657A5
Authority
JP
Japan
Prior art keywords
antibody according
heavy chain
light chain
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018085040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018121657A (ja
JP6638018B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018121657A publication Critical patent/JP2018121657A/ja
Publication of JP2018121657A5 publication Critical patent/JP2018121657A5/ja
Application granted granted Critical
Publication of JP6638018B2 publication Critical patent/JP6638018B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018085040A 2011-06-02 2018-04-26 Fcレセプター結合タンパク質 Active JP6638018B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161492617P 2011-06-02 2011-06-02
US61/492,617 2011-06-02
US201161498266P 2011-06-17 2011-06-17
US61/498,266 2011-06-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017037848A Division JP6334763B6 (ja) 2011-06-02 2017-03-01 Fcレセプター結合タンパク質

Publications (3)

Publication Number Publication Date
JP2018121657A JP2018121657A (ja) 2018-08-09
JP2018121657A5 true JP2018121657A5 (enExample) 2019-05-09
JP6638018B2 JP6638018B2 (ja) 2020-01-29

Family

ID=47259886

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014513732A Active JP6104897B2 (ja) 2011-06-02 2012-06-01 Fcレセプター結合タンパク質
JP2017037848A Active JP6334763B6 (ja) 2011-06-02 2017-03-01 Fcレセプター結合タンパク質
JP2018085040A Active JP6638018B2 (ja) 2011-06-02 2018-04-26 Fcレセプター結合タンパク質

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014513732A Active JP6104897B2 (ja) 2011-06-02 2012-06-01 Fcレセプター結合タンパク質
JP2017037848A Active JP6334763B6 (ja) 2011-06-02 2017-03-01 Fcレセプター結合タンパク質

Country Status (14)

Country Link
US (6) US9359438B2 (enExample)
EP (2) EP2966089B1 (enExample)
JP (3) JP6104897B2 (enExample)
KR (1) KR102014554B1 (enExample)
CN (2) CN103619353B (enExample)
AU (2) AU2012262007B2 (enExample)
BR (1) BR112013030352B1 (enExample)
CA (1) CA2837527C (enExample)
ES (1) ES2748583T3 (enExample)
IL (1) IL229618B (enExample)
MX (1) MX343659B (enExample)
PH (1) PH12013502378A1 (enExample)
SG (2) SG195025A1 (enExample)
WO (1) WO2012167039A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273351B2 (en) * 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
BR112013030352B1 (pt) 2011-06-02 2020-05-19 Dyax Corp. anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) * 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
EP4053560A1 (en) 2013-11-26 2022-09-07 The Brigham and Women's Hospital, Inc. Compositions and methods for modulating an immune response
EP4241852A3 (en) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
JP6853178B2 (ja) 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド FcRn抗体およびその使用方法
KR20190015704A (ko) * 2016-04-25 2019-02-14 신티뮨, 인크. 인간화된 친화성 성숙 항-fcrn 항체
BR112019001806A2 (pt) * 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
WO2018100146A1 (en) 2016-12-01 2018-06-07 Sabic Global Technologies B.V. Hybrid composite tailgate
MX2019015065A (es) * 2017-06-15 2020-08-03 UCB Biopharma SRL Metodo para tratamiento de trombocitopenia inmunitaria.
MA51032A (fr) 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
JP7486437B2 (ja) 2018-06-08 2024-05-17 アルジェニクス ビーブイ 免疫性血小板減少症を治療する組成物及び方法
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
WO2021012176A1 (en) * 2019-07-23 2021-01-28 Shanghaitech University Asic1 channel antagonist antibody
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
CA3183153A1 (en) 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
CN116888473A (zh) * 2021-02-18 2023-10-13 豪夫迈·罗氏有限公司 用于解析复杂、多步骤抗体相互作用的方法
TW202305361A (zh) * 2021-04-14 2023-02-01 美商建南德克公司 預測生物製劑之藥物動力學及腦滲透性之活體外基於細胞之測定
US20230212316A1 (en) * 2021-12-15 2023-07-06 Wisconsin Alumni Research Foundation IgG EPITOPE PEPTIDES THAT BIND RHEUMATOID FACTOR AND METHODS OF USE THEREOF
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
KR20250037789A (ko) 2022-06-15 2025-03-18 아르젠엑스 비브이 Fcrn/항원-결합 분자 및 사용 방법
IL328082A (en) 2023-11-06 2026-06-01 Momenta Pharmaceuticals Inc Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2026083290A1 (en) 2024-10-16 2026-04-23 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
CN119490588B (zh) * 2024-10-17 2026-03-06 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
DE2901218A1 (de) 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab Ung von theophyllin
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE81724T1 (de) 1987-11-09 1992-11-15 Becton Dickinson Co Verfahren zur analyse haematopoietischer zellen in einer probe.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5179107A (en) 1990-09-07 1993-01-12 Schering Corporation Antiviral quinolinone compounds
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
EP1068356B8 (en) 1998-04-03 2007-01-03 Adnexus Therapeutics, Inc. Addressable protein arrays
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6960178B2 (en) 2000-02-02 2005-11-01 Xepmed, Inc. Apparatus for enhanced plasmapheresis and methods thereof
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
PT1916001E (pt) 2002-03-04 2011-07-18 Imclone Llc Anticorpos humanos específicos para kdr e suas utilizações
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CA2534973A1 (en) 2003-08-08 2005-02-17 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatment of auto/allo immune conditions
JP2008538919A (ja) * 2005-04-29 2008-11-13 ザ ジャクソン ラボラトリー FcRn抗体およびその使用
CA2637929A1 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
US20070181136A1 (en) 2006-02-08 2007-08-09 Gelb Michael L Oral appliance
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US8273351B2 (en) 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
US8537763B2 (en) 2008-06-30 2013-09-17 Motorola Mobility Llc Frame allocation to support legacy wireless communication protocols on uplink transmission
ES2613841T3 (es) * 2008-07-16 2017-05-26 Medical And Biological Laboratories Co., Ltd. Anticuerpo anti-CLCP1 humano y uso del mismo
TW201029662A (en) * 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
JP5717624B2 (ja) * 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
BR112013030352B1 (pt) 2011-06-02 2020-05-19 Dyax Corp. anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
KR20200014379A (ko) 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
JP7486437B2 (ja) 2018-06-08 2024-05-17 アルジェニクス ビーブイ 免疫性血小板減少症を治療する組成物及び方法

Similar Documents

Publication Publication Date Title
JP2014518883A5 (enExample)
WO2022135536A1 (zh) Cd3人源化抗体及其应用
JP2020536488A5 (enExample)
US10894828B2 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
JP2015163068A5 (enExample)
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
JP2012501670A5 (enExample)
FI3525583T3 (fi) Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
JP2018510636A5 (enExample)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2014111644A5 (enExample)
JP2017531427A5 (enExample)
JP2017149720A5 (enExample)
JP2012116856A5 (enExample)
JP2021502984A5 (enExample)
JP2011509245A5 (enExample)
JP2019523221A5 (enExample)
JP2015525208A5 (enExample)
JP2013545455A5 (enExample)
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
CA2896548A1 (en) Multivalent binding protein compositions
RU2016100892A (ru) Антитела против tweakr и их применение
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
JP2021500916A5 (enExample)
JP2014518615A5 (enExample)